Cervical Cancer Screening in India: Tests That Save Lives

• Cervical cancer is almost entirely caused by persistent high-risk HPV infection, and it develops slowly over 10 to 20 years, which is exactly why screening can catch it before it becomes cancer.
• India offers three screening tests: VIA (visual inspection with acetic acid), the Pap smear, and the HPV DNA test, which FOGSI now recommends as the preferred primary screen from age 30.
• Most women should start screening at 30, repeat every 3 to 5 years depending on the test, and continue to about 65 if results stay normal.
• An abnormal result is not a cancer diagnosis; it is a flag for a colposcopy and biopsy, and pre-cancer found this way is highly treatable with LEEP, cryotherapy, or thermal ablation.
• Vaccination does not replace screening, and screening is recommended for all women from 30 regardless of marital or sexual history.
• Bleeding after sex, bleeding between periods, or any bleeding after menopause needs a gynaecologist promptly, even though early cervical cancer usually has no symptoms at all.

India carries one of the heaviest cervical cancer burdens in the world. Around 96,000 women are newly diagnosed each year and roughly 60,000 die from it, according to the Indian Council of Medical Research's National Cancer Registry Programme. That is one Indian woman lost roughly every nine minutes to a cancer we know how to prevent.

Globally, India accounts for close to a quarter of all cervical cancer deaths, even though Indian women make up about a sixth of the world's female population. The reason is not biology, it is access. Countries with organised screening programmes have cut their cervical cancer rates dramatically, while India's national screening coverage still sits in the low single digits.

What makes this disease preventable is how slowly it moves. Cervical cancer is almost never sudden. It begins with a common infection, drifts through a multi-year pre-cancer phase that has no symptoms, and only becomes invasive cancer 10 to 20 years later. Almost every woman who develops invasive cervical cancer passed through a window, sometimes a decade long, during which a single screening test could have caught it.

Most deaths in India happen because women are diagnosed too late. Stage I cervical cancer has a 5-year survival of around 90 percent; by Stage IV it falls to roughly 15 percent. The screening test is what moves a woman from one column to the other. Understanding cervical cancer risk factors such as smoking and HIV helps, but screening protects every woman regardless of her risk profile.

Cervical cancer is caused almost entirely by persistent infection with high-risk human papillomavirus (HPV). HPV 16 and HPV 18 alone are responsible for around 70 percent of cases worldwide and in India. A further share comes from five other high-risk strains: HPV 31, 33, 45, 52, and 58.

HPV itself is extremely common. Most sexually active adults will encounter it at some point, and in the great majority the immune system clears it silently within a year or two. The problem is the small fraction in whom a high-risk strain lingers. Over 5 to 20 years, persistent infection nudges normal cervical cells through pre-cancer stages, called CIN 1, CIN 2, and CIN 3, and eventually into invasive cancer. You can read more about the virus itself in our guide to HPV types, symptoms, and treatment.

This long, slow timeline is the gift cervical cancer gives us. A persistent HPV infection picked up by an HPV DNA test, or a pre-cancer change spotted on a Pap smear or VIA exam, can be treated long before it ever becomes cancer. The screening test does not just find cancer earlier; it usually finds it before it is cancer at all.

Factors that raise the chance of persistent HPV and progression include smoking, a weakened immune system (including HIV), long-term oral contraceptive use, multiple childbirths, and other genital infections. None of these change the central fact that HPV is the cause, and almost the entire prevention story runs through vaccination and screening. Women living with HIV are at particularly high risk, which is why HIV prevention and care for women in India and earlier, more frequent screening go hand in hand.

• VIA (Visual Inspection with Acetic Acid): a trained provider applies dilute vinegar to the cervix during a speculum exam. Pre-cancer areas turn briefly white and are visible to the naked eye. It is single-visit, low-cost, and the backbone of government PHC and CHC programmes, with sensitivity around 70 percent.
• Pap smear (cervical cytology): a small brush collects cells from the cervix, which are sent to a lab. This has been the standard screening test globally since the 1940s. Sensitivity is 50 to 70 percent on a single test, which is why it is repeated every 3 years. It is free at government centres and roughly 500 to 2,000 rupees at private labs.
• HPV DNA test: a swab from the cervix is tested for high-risk HPV strains. Sensitivity is above 90 percent. FOGSI now recommends HPV DNA as the preferred primary screen for women aged 30 and above where available. Private cost is around 1,500 to 3,500 rupees.
• HPV plus Pap co-test: the most sensitive option, combining both, and recommended every 5 years if both come back negative. It is most often used at private hospital chains and in higher-income screening pathways.
• Self-sampling HPV kits are now emerging in India through some clinics and digital health platforms. The woman collects her own vaginal swab in private and sends it to a lab. Studies show acceptability is high and accuracy is comparable to a clinician-collected sample, making it a powerful tool for reaching women who avoid speculum exams.

Visual Inspection with Acetic Acid is the screening test most likely to reach the largest number of Indian women in the next decade. It is cheap, needs no laboratory infrastructure, gives results in the same visit, and can be performed by trained nurses and ANMs, not only doctors.

The exam itself takes about 5 to 10 minutes. A speculum is inserted, the cervix is wiped with 3 to 5 percent acetic acid (essentially dilute white vinegar), and the provider watches for any area to turn white. This whitening, called an acetowhite change, appears within about a minute over any patch of cells that may be pre-cancerous.

If the cervix looks normal, the result is negative and the woman is asked to return in 3 to 5 years. If a white patch is seen, she is referred for confirmation by colposcopy or biopsy, or in some single-visit see-and-treat programmes, treated immediately with cryotherapy or thermal ablation on the same day.

VIA is not perfect. It catches about 70 percent of pre-cancer lesions and has a higher false-positive rate than Pap or HPV testing. But in the Indian context, where most women have never had any screening at all, even an imperfect test that reaches a hundred million women is a transformational improvement over a perfect test that reaches only a few lakhs.

A Pap smear is what most urban Indian women will encounter at a private gynaecology clinic. The test takes about 5 minutes and is uncomfortable rather than painful. You lie on an exam couch, a speculum is gently inserted, and a soft brush sweeps cells from the outer cervix and the cervical canal. The cells go onto a slide or into a liquid medium and are sent to a cytology lab.

Results usually come back in 1 to 2 weeks. They are reported using the Bethesda system, with terms such as NILM (normal), ASCUS (mild changes, uncertain meaning), LSIL (low-grade changes), HSIL (high-grade changes), and AGC (changes in glandular cells).

Try to schedule the test when you are not on your period. Avoid intercourse, vaginal medicines, douching, or tampon use for 24 to 48 hours before. None of these absolutely prevent the test, but they can sometimes blur the result.

If you have never had a Pap smear before and feel anxious, that is completely normal. For a fuller first-time guide, including how to ask for it, what the room looks like, and how to advocate for yourself if a provider rushes, see our walkthrough of your first Pap smear in India. If you have never seen a gynaecologist at all, our guide to the first gynae visit in India covers what to expect.

The HPV DNA test directly detects high-risk HPV strains in cervical cells, rather than waiting to see if those strains have already started changing the cells. Because it catches the cause and not just the consequence, its sensitivity is above 90 percent, far higher than Pap or VIA.

The collection is identical to a Pap smear: speculum, brush, cervical swab. In many private labs the same sample can be tested for both HPV and cytology, and that combination is the co-test. The result is usually reported as HPV positive or negative, sometimes with the specific strain (16, 18, or other high-risk).

FOGSI's guidelines now position HPV DNA testing as the preferred primary screen for women aged 30 and above, with Pap as the next-best alternative and VIA where neither is available. The World Health Organization has been making the same shift globally.

A negative HPV test buys you a long interval; most guidelines recommend the next screen 5 years later. A positive HPV test does not mean cancer. It means you are at higher risk and need a Pap smear, a repeat HPV test, or a colposcopy depending on your age and the specific strain. For help making sense of the lab and scan reports your gynaecologist may order during this workup, see understanding your scans, labs, and reports.

• Start at age 30. FOGSI, the Indian Council of Medical Research, and WHO align on age 30 as the starting point for the general population. Earlier screening is not recommended because pre-cancer changes before 30 usually resolve on their own.
• Screen earlier if higher risk. Women living with HIV, organ transplant recipients, women on long-term immunosuppressive medication, and those with a previous abnormal result should start earlier and screen more often, usually annually after an HIV diagnosis.
• Frequency depends on the test: HPV DNA every 5 years if negative; Pap every 3 years if negative; VIA every 3 to 5 years if negative; HPV plus Pap co-test every 5 years if both negative.
• Stop at age 65 if your last three screens were consistently normal and you have no history of CIN 2 or worse. Women with a history of significant pre-cancer should keep screening for at least 25 years after that diagnosis, regardless of age.
• Pregnancy is not a reason to skip a due Pap smear; it is safe during routine antenatal care, and HPV testing is also safe in pregnancy.
• Vaccination does not replace screening. Even a fully vaccinated woman should still screen from age 30, because the vaccine does not cover every cancer-causing HPV strain.
• A hysterectomy that removed the cervix for a benign reason, such as fibroids, usually means cervical screening can stop. If the cervix was left in place, or the surgery was for a cancer-related reason, screening continues.

An abnormal screening result is not a cancer diagnosis. It is a flag that says further investigation is needed, and the next step depends on exactly what was abnormal and on your age. Most women with an abnormal result do not have cancer, and many changes resolve on their own.

ASCUS on a Pap, or a positive HPV test with a non-16/18 strain, usually means a repeat Pap or HPV test in 6 to 12 months, or a colposcopy depending on the lab's local protocol. LSIL on a Pap usually leads to a colposcopy, though around 60 percent of LSIL changes regress on their own in younger women, so monitoring is often appropriate. HSIL on a Pap, or an HPV 16 or 18 positive result, means a colposcopy with biopsy is strongly recommended without delay. We explain each of these categories in more depth in our guide to an abnormal Pap smear and what happens next.

Colposcopy is a 15 to 20 minute outpatient exam in which a magnifying device is used to inspect the cervix in detail, and small biopsies may be taken from suspicious areas. For costs and a step-by-step description, see our guide to colposcopy in India: procedure and cost.

Biopsy results are graded as CIN 1, CIN 2, or CIN 3. CIN 1 is mild dysplasia and most often resolves on its own with monitoring every 6 to 12 months. CIN 2 and CIN 3 are moderate-to-severe pre-cancer and need treatment to prevent progression. Our guide to cervical dysplasia explains these pre-cancer grades and how they are managed.

• LEEP (Loop Electrosurgical Excision Procedure) is the most common treatment for CIN 2 and CIN 3 in India. A thin wire loop heated by an electric current shaves off the abnormal area. It is done in an outpatient setting under local anaesthesia and takes about 20 minutes. Cost is roughly 8,000 to 25,000 rupees at private centres and free at most government cancer hospitals.
• Cryotherapy freezes the abnormal tissue with a probe cooled by nitrous oxide or carbon dioxide. It is simple, cheap, and well-suited to single-visit see-and-treat programmes where a VIA-positive woman is treated on the same day. Cost is around 3,000 to 8,000 rupees privately and free in government programmes.
• Cone biopsy (conization) removes a cone-shaped piece of cervical tissue. It is used when the lesion extends into the cervical canal, when LEEP cannot reach it, or when microinvasion is suspected. It is done in an operating theatre under regional or general anaesthesia, at around 15,000 to 40,000 rupees privately.
• Thermal ablation (thermocoagulation) is a newer alternative to cryotherapy that uses heat instead of cold. It is being increasingly adopted in India because it does not need gas cylinders and is more portable for rural programmes.
• After any pre-cancer treatment, follow-up screening is required at 6 to 12 months and then at regular intervals, to make sure the lesion does not return. Most pre-cancer treatments are highly successful, with recurrence rates after LEEP well below 10 percent.

Invasive cervical cancer is staged from I to IV based on how far it has spread. Stage I is confined to the cervix; Stage II spreads to the upper vagina or surrounding tissue; Stage III reaches the lower vagina or pelvic wall; Stage IV has spread to the bladder, rectum, or distant organs.

Stage I and early Stage IIA are usually treated with radical hysterectomy plus pelvic lymph node dissection, removing the uterus, cervix, upper vagina, and nearby lymph nodes. For very early Stage IA with no fertility plans, a simple hysterectomy may be enough. For young women who want future fertility, a trachelectomy (removing the cervix but leaving the uterus) is possible in selected cases at specialised centres.

Stage IIB and above are usually treated with chemoradiation, which combines external beam radiation, internal brachytherapy, and cisplatin chemotherapy. Surgery is usually not the primary tool at these stages because the cancer has spread beyond surgical reach. Stage IV often involves a combination of chemotherapy, radiation, and palliative care depending on the spread, and newer immunotherapy options such as pembrolizumab are being used in selected advanced cases at major Indian cancer centres.

Survival depends heavily on stage at diagnosis. Stage I cervical cancer has a 5-year survival of around 90 percent, Stage II around 60 to 70 percent, Stage III around 30 to 50 percent, and Stage IV around 15 percent. Every step earlier in screening genuinely changes the outcome. Treatment in India is best done at a comprehensive cancer centre with a gynaecologic oncology unit, such as Tata Memorial Mumbai, Kidwai in Bengaluru, the Cancer Institute (WIA) Chennai, AIIMS Delhi, RCC Thiruvananthapuram, and various Apollo and HCG centres.

• Ayushman Bharat PMJAY covers cervical cancer screening, diagnosis, and treatment for eligible families, including surgery, radiation, and chemotherapy. Cashless treatment is available at empanelled hospitals across India.
• Government cancer hospitals offer free or heavily subsidised treatment regardless of PMJAY status, including Tata Memorial Mumbai, Kidwai Bengaluru, the Cancer Institute (WIA) Chennai, RCC Thiruvananthapuram, and AIIMS Delhi.
• Cervavac, the Indian HPV vaccine launched by the Serum Institute of India in 2022, is the cheapest entry point to prevention at around 2,000 rupees per dose. The government has announced a phased national rollout for girls aged 9 to 14 under the Universal Immunisation Programme.
• Screening is free at most government primary health centres (PHCs) and community health centres (CHCs) through the national cancer screening programme. Coverage is patchy by state but expanding.
• Many private hospital chains now bundle a screening package, such as a Pap smear or HPV test plus a gynaecology consultation, for 1,500 to 4,000 rupees, often as part of an annual women's wellness check-up.
• The WHO 90-70-90 elimination strategy targets 90 percent HPV vaccination of girls by age 15, 70 percent screening of women by ages 35 and 45, and 90 percent treatment of those who need it, by 2030. India's national programme is built around moving toward these numbers.

• Myth: no symptoms means no risk. Fact: early-stage cervical cancer and pre-cancer have no symptoms at all. By the time symptoms appear, the disease is usually already advanced. Screening is what catches it during the silent phase.
• Myth: a Pap smear is very painful. Fact: it is uncomfortable for a few seconds, not painful. A good clinician explains every step, uses a small or warmed speculum, and goes slowly. If a previous Pap was painful, ask for a smaller speculum and a slower pace next time.
• Myth: screening is only for sexually active or married women. Fact: any woman who has ever had genital skin contact can carry HPV, and current Indian and global guidelines recommend screening for all women from age 30 onward, irrespective of marital or sexual history.
• Myth: if I had the HPV vaccine, I do not need screening. Fact: even Gardasil 9 covers nine HPV strains, but a share of cervical cancers come from strains outside the vaccine. Screening from age 30 stays essential for life.
• Myth: cervical cancer runs in families, and I have no family history. Fact: cervical cancer is overwhelmingly driven by HPV infection, not heredity. Almost any woman with a persistent high-risk HPV strain can develop it, with or without a family history.
• Myth: a screening visit will reveal that I am sexually active. Fact: a screening visit is a routine adult health check, framed exactly like a blood pressure check. You do not have to explain or justify it, and many clinics now offer women-only OPDs and discreet billing.

The hardest thing about cervical cancer is that the screening years, the years in which we can stop it, are completely silent. By the time the body produces symptoms, the cancer is almost always past the easily curable stage. That is the whole reason screening exists. Still, certain symptoms should always prompt a gynaecologist visit, even if you screened recently.

See a doctor promptly if you notice abnormal vaginal bleeding (between periods, after sex, or after menopause), foul-smelling vaginal discharge that does not respond to usual treatment, new or persistent pelvic pain, pain during intercourse, or unexplained leg swelling, which can occur in more advanced disease.

Bleeding after sex is the symptom most often dismissed. Many women assume it is normal, hormonal, or related to dryness. It is almost always not normal at any age and should always be checked; see our guide to bleeding after sex for the full picture. Postmenopausal bleeding is another red flag: any vaginal bleeding more than a year after your last period is abnormal and needs prompt review, both for cervical cancer and for endometrial (uterine) cancer. Persistent bloating or pelvic discomfort can also point to other gynaecological cancers, so it is worth knowing the early warning signs of ovarian cancer too.

Building the habit of noticing what has changed in your body protects you across the board. A monthly breast self-exam trains the same instinct. The principle is simple: anything new, persistent, or unexplained deserves a check, not a wait.

Cervical cancer takes around 60,000 Indian women a year, and almost every one of those deaths was preventable with a low-cost test taken on time.

If you are 30 or older, book a screening this year. Choose HPV DNA if you can access it, a Pap smear if not, and VIA if neither is available; any screening is dramatically better than none.

If your result comes back abnormal, do not panic and do not delay. Abnormal does not mean cancer. The next step is usually a colposcopy and biopsy, and pre-cancer found at this stage is highly treatable.

If there is a girl in your family aged 9 to 14, vaccinate her with Cervavac or Gardasil 9. Vaccination plus screening from age 30 is what closes the cervical cancer chapter for the next generation.

And if you have noticed bleeding after sex, bleeding between periods, bleeding after menopause, or persistent foul discharge, see a gynaecologist this week, not next month. Cervical cancer in its early stages is largely curable; often the only barrier between an Indian woman and a normal life expectancy is the time it takes her to be seen.

• WHO — Cervical cancer fact sheet
• WHO — Global strategy to accelerate the elimination of cervical cancer
• ICMR — Consolidated Guidelines for Prevention and Management of Common Cancers (cervix)
• FOGSI (Federation of Obstetric and Gynaecological Societies of India)
• American College of Obstetricians and Gynecologists (ACOG) — Cervical Cancer Screening
• NHS — Cervical screening
• National Health Mission, MoHFW — Operational Framework for Management of Common Cancers